Fachbereich Veterinärmedizin



    Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer (2011)

    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Schulz, Petra
    Fischer, Christian
    Detjen, Katharina M
    Rieke, Svenja
    Hilfenhaus, Georg
    von Marschall, Zofia
    Böhmig, Michael
    Koch, Inga
    Kehrberger, Jenny
    Hauff, Peter
    Thierauch, Karl Heinz
    Alves, Frauke
    Wiedenmann, Bertram
    Scholz, Arne
    The FASEB journal : official publ. of the Federation of American Societies for Experimental Biology; 25(10) — S. 3325–3335
    ISSN: 0892-6638
    DOI: 10.1096/fj.11-182287
    Pubmed: 21685330
    Institut für Pharmakologie und Toxikologie

    Koserstr. 20
    14195 Berlin
    Tel.+49 30 838 53221 Fax.+49 30 838 53112

    Abstract / Zusammenfassung

    Lymphatic metastasis constitutes a critical route of disease dissemination, which limits the prognosis of patients with pancreatic ductal adenocarcinoma (PDAC). As lymphangiogenesis has been implicated in stimulation of lymphatic metastasis by vascular endothelial growth factor-C (VEGF-C) and VEGF-D, we studied the effect of the angioregulatory growth factor angiopoietin-2 (Ang-2) on PDAC progression. Ang-2 was found to be expressed in transformed cells of human PDAC specimens, with corresponding Tie-2 receptors present on blood and lymphatic endothelium. In vitro in PDAC cells, Ang-2 was subject to autocrine/paracrine TGF-β stimulation (2-fold induction, P=0.0106) acting on the -61- to +476-bp element of the human Ang-2 promoter. In turn, Ang-2 regulated the expression of genes involved in cell motility and tumor suppression. Orthotopic PDAC xenografts with forced expression of Ang-2, but not Ang-1, displayed increased blood and lymphatic vessel density, and an enhanced rate of lymphatic metastasis (6.7- to 9.1-fold, P<0.01), which was prevented by sequestration of Ang-2 via coexpression of soluble Tie-2. Notably, elevated circulating Ang-2 in patients with PDAC correlated with the extent of lymphatic metastasis. Furthermore, median survival was reduced from 28.4 to 7.7 mo in patients with circulating Ang-2 ≥ 75th percentile (P=0.0005). These findings indicate that Ang-2 participates in the control of lymphatic metastasis, constitutes a noninvasive prognostic biomarker, and may provide an accessible therapeutic target in PDAC.